Type almost any peptide name into a search bar in September 2026 and the answer you get back will contain the word approved, or something built to sound like it. Cleared. Greenlit. Back. Legal again. Of the eleven compounds people search for most, exactly one is an FDA-approved drug that a US pharmacy can dispense today under its own brand, and it is approved for a single indication that has nothing to do with why most people are searching.
So this is a reference piece with a thesis attached. Every peptide in the current conversation sits in one of three buckets: approved, recommended, or neither. The first and third buckets are easy to understand. The middle one is where the confusion lives, and I think it is doing more damage than either of the others, because "recommended by an FDA advisory committee" sounds like the first bucket and has the legal content of the third.
What follows states regulatory status only. It does not describe what anyone uses these compounds for, and nothing here is a suggestion to use any of them. Status is the one question on which a straight answer exists, and it is the one almost nobody selling into this market gives.
Three legal doors, and why most peptides have only one
A licensed pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act can only use a bulk ingredient that clears one of three gates. It has a monograph in the United States Pharmacopeia. It is a component of an FDA-approved drug. Or it appears on the 503A Bulks List, which the FDA can only amend through a final rule.
Most of the peptides in this piece fail the first two gates, which leaves the list. That list has admitted six substances since 1997, all in a single rule published on 19 February 2019, and none of them is a peptide. A second batch proposed on 5 September 2019 is still a proposal. Keep that speed in mind for everything below.
Bucket one: approved, and narrower than the marketing
Tesamorelin is the only compound on the list that is an FDA-approved drug on the market today. It was first approved in 2010 as Egrifta, reformulated as Egrifta SV in 2019, and approved again in a more concentrated form, Egrifta WR, on 25 March 2025. Across all three versions the indication has never moved: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label states that it is not indicated for weight loss management. Approval is specific to an indication, a formulation and a labelled population. It is not a general verdict on the molecule.
Sermorelin is the strange case. It was approved as Geref under NDA 20-443, and EMD Serono discontinued it in December 2008. In a Federal Register notice dated 4 March 2013, the FDA determined that Geref was not withdrawn for reasons of safety or effectiveness. That determination matters, because it keeps sermorelin inside the second gate: a component of an FDA-approved drug. So sermorelin is compounded under prescription today through a door that none of the other peptides here can use. There is no FDA-approved sermorelin product currently on the market. "Formerly approved, currently compoundable" is its accurate description, and it is not the same thing as "approved".
For completeness: semaglutide and tirzepatide are peptides and are approved, and so is bremelanotide, sold as Vyleesi since June 2019. They sit in this bucket because their manufacturers ran the trials. That is the whole distinction, and it is worth remembering how expensive and slow it was for them.
Bucket two: recommended, which is not a legal status
On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee voted in favour of six peptides for the 503A Bulks List. BPC-157, KPV and TB-500 passed 8 to 6 with one abstention. MOTS-c passed 7 to 5 with two abstentions. Semax passed 8 to 5 and Epitalon 7 to 4. Emideltide, also known as DSIP, failed. The FDA's own scientific reviewers had argued against the six that passed.
Here is what that vote changed legally: nothing yet. Committee recommendations are not binding on the FDA. Adding a substance to the list requires formal notice-and-comment rulemaking, and HHS still has to act. Until a final rule is published, none of these six can lawfully be compounded on the strength of the vote, and the agency keeps its enforcement authority.
There is a second layer of confusion underneath. In late April 2026 twelve peptides came off Category 2, the FDA's interim list of substances with significant safety concerns, after the parties that had nominated them withdrew those nominations. Coming off Category 2 means the agency stopped flagging a substance on safety grounds while it evaluates it. It does not put the substance on the list, and none of the twelve had ever been in Category 1, the tolerated category. The phrase "restored access", which appears on a great many commercial pages, describes something that did not happen.
I think bucket two is the most important one in this piece, and the most underrated fact about it is how empty it is. It is a waiting room. The last cohort to sit in it, the five substances in the 2019 proposed rule, has been waiting seven years.
Bucket three: neither, and two very different kinds of neither
The first kind of "neither" is already rejected. The same committee reviewed ipamorelin on 29 October 2024 and voted against adding it to the list. On 4 December 2024 it voted against CJC-1295 and AOD-9604, both by unanimous margins according to published accounts, and against thymosin alpha-1 as well. These compounds are not waiting for anything. They have been heard and turned down, which is a clearer answer than anything in bucket two, and yet they circulate online under the same "grey area" vocabulary as everything else.
The second kind is not yet heard. GHK-Cu in injectable form is one of five peptides, alongside melanotan II, cathelicidin LL-37, dihexa acetate and PEG-MGF, that the FDA has said it will put before the committee before the end of February 2027. Until then it has no recommendation and no listing. GHK-Cu also appears widely as a topical cosmetic ingredient, which is a separate regulatory world and says nothing about its status as a compounded drug.
One more quiet change sits over this bucket. Since 7 January 2025, the FDA no longer assigns interim categories to newly nominated bulk substances. The informal corridor in which a compound could be described as "under review, so tolerated" has been narrowing for nearly two years.
The strongest case against sorting it this way
The fair objection is that three buckets flatten real differences. A peptide with small human studies and a peptide with none land in the same middle bucket. A drug approved for one narrow indication and a compound voted down unanimously both get a single word. And a sceptic of the FDA would add that "approved" is itself a political outcome, shaped by who can afford trials, not a pure measure of safety.
I take the last point seriously. Approval does reflect money as much as science, and the July vote showed how much committee composition can move an outcome. But the buckets are not a ranking of how good a molecule is. They answer a narrower question: what can a licensed pharmacy legally do with it today. On that question the sorting is not a simplification. It is the law as written, and the market has a strong commercial reason to blur it.
What the sorting tells you
Count it up. One compound approved and on the market, for one indication. One formerly approved and compoundable through a door the others cannot use. Six recommended and waiting on a rulemaking process that has produced one final rule in twenty-nine years. Three that are neither, two of them already voted down.
That is the actual map of the eleven peptides people search for most. It is less exciting than the pages that rank for "is BPC-157 legal", and I think that is exactly the point: the most useful sentence in this whole field is also the least profitable one to write. We will keep writing it, and updating this sorting as the FDA acts. The monthly letter is where those updates land first.
Ozemback, September 2026